The Role of HIPEC in Colon Cancer: Retrospective Analysis of 15 Cases

Objectives: To evaluate the outcomes of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery in patients with peritoneal carcinomatosis secondary to colon cancer treated at Bharath Cancer Hospital over one year. Material and Methods: From August 2022 to August 2023, 15 patients with colon cancer and confirmed peritoneal metastasis underwent cytoreductive surgery followed by HIPEC using Mitomycin C and Oxaliplatin. Inclusion criteria consisted of peritoneal metastasis without extraperitoneal disease, good performance status, and the feasibility of achieving complete cytoreduction (CC-0 or CC-1). The Peritoneal Cancer Index (PCI) was used to assess disease burden. Results: The average patient age was 56 years, with PCI scores ranging from 8 to 20. Complete cytoreduction (CC-0) was achieved in 73.3% of patients. The average operative time was 8 hours. Postoperative complications occurred in 33.3% of patients, with no perioperative or 30-day mortality. Peritoneal recurrence occurred in 20% of cases. Conclusion: HIPEC, when combined with cytoreductive surgery, demonstrates promising short-term outcomes in selected patients with peritoneal carcinomatosis from colon cancer. Although the recurrence rate was relatively low, further research is necessary to confirm long-term benefits and refine patient selection criteria.